Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis patients with renal anemia affected by the COVID-19 pandemic: a retrospective study | Zendy

Lingling Bao | Zendy; Xueyan Bian | Zendy; Aiwei Zhang | Zendy; Jiancheng Huang | Zendy; Liling Ren | Zendy; Chunlei Luo | Zendy

Open Access

Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis patients with renal anemia affected by the COVID-19 pandemic: a retrospective study

Author(s) -

Lingling Bao,

Xueyan Bian,

Aiwei Zhang,

Jiancheng Huang,

Liling Ren,

Chunlei Luo

Publication year - 2022

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-22-555

Subject(s) - medicine , peritoneal dialysis , anemia , erythropoietin , intensive care medicine , dialysis , pandemic , compliance (psychology) , kidney disease , disease , covid-19 , infectious disease (medical specialty) , psychology , social psychology

Current studies have limited data on long-term treatment safety and medication compliance of roxadustat for renal anemia in peritoneal dialysis (PD) patients. We aimed to analyze the long-term efficacy, safety, and medication compliance of roxadustat in the treatment of renal anemia in patients with PD who discontinued recombinant human erythropoietin (rhEPO) treatment due to the corona virus disease 2019 (COVID-19) outbreak.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research